GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Demand for the marijuana drug developer's treatment for epilepsy caused shares to skyrocket last quarter.

Marijuana Stock GW Pharmaceuticals Delivers Rapid Growth In Q1

Late Monday, GW Pharmaceuticals reported a net loss of 2 cents per share on $120.6 million in sales for its first quarter. In response, GWPH stock popped.

GW Pharmaceuticals Pops After Cannabis Drug Outsells Expectations

GW Pharmaceuticals PLC GWPH, +0.68% shares rose 2.6% in the extended session Monday after the U.K.

GW Pharmaceuticals sells more of CBD-derived epilepsy drug than expected, stock rises

GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.

What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings?

It isn’t turning a profit yet, but its revenue is about to jump.

Is It Time to Get in on GW Pharmaceuticals While the Price Is Right?

GW Pharmaceuticals Q1 Results Will Provide Important Markers For The Coming Year

Aurora Cannabis

Aphria

Canopy Growth

Cronos Group

Cannabis short sellers got off to a hot start in 2020 after netting nearly $1 billion in profits in 2019.

Cannabis Stock Rally Puts Short Sellers In The Red For 2020

Ameresco

Cardtronics

eHealth

HCA Healthcare

Restaurant Brands

UroGen Pharma

Whether or not a recovery is imminent, there are compelling stocks to buy, it’s just a matter of where you look for them.

7 Stocks to Buy for Their Double-Digit Growth Prospects

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Innovative Industrial Properties

Trulieve Cannabis Corp.

Previous highfliers Aurora Cannabis and Tilray no longer make the list.

Marijuana's Billion-Dollar Pot Stocks: Only 7 Remain

GW Pharma (GWPH) news for Monday concerning the descheduling of Epidiolex as a Schedule V drug by the DEA has GWPH stock rising.
The post GW Pharma News: GWPH Stock Jumps 6% on Epidiolex Descheduling by DEA appeared first on InvestorPlace.

GW Pharma News: GWPH Stock Jumps 6% on Epidiolex Descheduling by DEA

Marketing Epidiolex is about to get a lot easier for GW Pharmaceuticals.

The DEA Has Descheduled Prescription CBD for Severe Epilepsy

- Descheduling will enable prescribing free of the previous Schedule V requirements -

GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc.

PDUFA date of July 31, 2020 PDUFA date of July 31, 2020

GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

2 Excessive Dips Provide A Very Good Buying Opportunity: GW Pharmaceuticals

GW Pharmaceuticals and its CBD oil are immune to coronavirus, according to an analyst — prodding GWPH stock to briefly pop Monday. The CBD oil, Epidiolex, treats several forms of epilepsy.

Why This Biotech Stock And Its CBD Oil Are Immune To Coronavirus

Epidiolex's growing sales aren't enough to help GW Pharma beat the market.

Is This the Most Undervalued Cannabis Stock?

Biogen

Vertex Pharmaceuticals

A rebounding stock market lifted all three of these biotech stocks.

Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped Today

There are some good deals out there right now.

2 Dirt-Cheap Cannabis Stocks to Buy Right Now

LONDON, March  13, 2020  (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition and a leading cause of genetic epilepsy. If approved, this will be the third licensed indication for GW’s cannabidiol oral solution in Europe.

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

Tilray Brands

Cannabis stock valuations have gone up in smoke.

There Were Once 20 Pot Stocks With a $1 Billion Valuation or Higher. Only 8 Remain.

AbbVie

Agenus

Atreca

Bicycle Therapeutics Plc - ADR

Bristol-Myers

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals Inc

Amicus Therapeutics

OrganiGram Holdings Inc.

Pfizer

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

GW Pharmaceuticals' stock took a beating last month. Here's why.

Why GW Pharmaceuticals Stock Plunged in February

Shopify

Investing directly in cannabis producers hasn't exactly been safe.

3 Ways to Benefit From the Cannabis Industry's Growth Without Taking on Much Risk

Disney

The market is still dealing with COVID19 (coronavirus issues) so we're talking about how marijuana is still a market mystery, Marijuana Innovators Editor Dave Borun joins us to shed some light on the subject.

Marijuana is Growing Cash, Can We Get In?

Patients are better off using pharmaceutical CBD than artisanal forms.

News for GW Pharmaceuticals Stock (GWPH)